CA2586621A1 - Contrast agents to target extracellular matrix - Google Patents

Contrast agents to target extracellular matrix Download PDF

Info

Publication number
CA2586621A1
CA2586621A1 CA002586621A CA2586621A CA2586621A1 CA 2586621 A1 CA2586621 A1 CA 2586621A1 CA 002586621 A CA002586621 A CA 002586621A CA 2586621 A CA2586621 A CA 2586621A CA 2586621 A1 CA2586621 A1 CA 2586621A1
Authority
CA
Canada
Prior art keywords
contrast agent
formula
moiety
moieties
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002586621A
Other languages
English (en)
French (fr)
Inventor
Dagfinn Lovhaug
Morten Eriksen
Hege B. Fjerdingstad
Andrew Healey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2586621A1 publication Critical patent/CA2586621A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
CA002586621A 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix Abandoned CA2586621A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
NO20045081 2004-11-22
PCT/NO2005/000435 WO2006054904A2 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Publications (1)

Publication Number Publication Date
CA2586621A1 true CA2586621A1 (en) 2006-05-26

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002586621A Abandoned CA2586621A1 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Country Status (17)

Country Link
US (1) US8182790B2 (https=)
EP (2) EP1814598B1 (https=)
JP (2) JP5116480B2 (https=)
KR (1) KR20070091609A (https=)
CN (1) CN101107016B (https=)
AT (1) ATE494913T1 (https=)
AU (1) AU2005307195A1 (https=)
BR (1) BRPI0518328A2 (https=)
CA (1) CA2586621A1 (https=)
DE (1) DE602005025911D1 (https=)
ES (1) ES2358745T3 (https=)
IL (1) IL182898A0 (https=)
MX (1) MX2007006050A (https=)
NO (1) NO20073039L (https=)
RU (1) RU2007118385A (https=)
WO (1) WO2006054904A2 (https=)
ZA (1) ZA200705043B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102504603A (zh) * 2011-10-20 2012-06-20 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20100233082A1 (en) * 2006-08-28 2010-09-16 Bengt Langstrom 68GA-Labeled Peptide-Based Radiopharmaceuticals
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
WO2009074628A1 (en) * 2007-12-13 2009-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
ES2658852T3 (es) 2008-01-18 2018-03-12 Visen Medical, Inc. Agentes de imaginología fluorescentes
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
WO2015085005A1 (en) * 2013-12-03 2015-06-11 The General Hospital Corporation Molecular imaging probes
CN117623996B (zh) * 2022-08-10 2025-07-22 中国药科大学 一种二价keap1-nrf2抑制剂、制备方法及其医药用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
JP3038339B2 (ja) 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
JP3682974B2 (ja) 1991-11-27 2005-08-17 株式会社ファノスディベロップメント バイオ作用性物質をバイオ粒子表面膜へ結合するための化合物、組成、および方法
BR9713978A (pt) 1996-10-28 2000-05-02 Nycomed Imaging As Agente diagnóstico alvejável e/ou terapeuticamente ativo, processo para preparação e uso do mesmo, formulação combinada, e, processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente
ES2257771T3 (es) * 1996-10-28 2006-08-01 Amersham Health As Agentes de contraste.
EP1011736A2 (en) * 1997-01-29 2000-06-28 Nycomed Imaging As Polymers
US6348599B1 (en) 1997-07-28 2002-02-19 Nycomed Amersham Plc Cyanine dyes
US5942637A (en) 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
CA2328414C (en) * 1998-05-08 2014-04-15 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
CN1230441C (zh) * 2000-04-12 2005-12-07 安盛药业有限公司 结合整联蛋白的肽衍生物
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
WO2002055111A2 (en) * 2000-11-27 2002-07-18 Bristol Myers Squibb Medical I Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
AU2003239030A1 (en) 2002-06-17 2003-12-31 Cartela R & D Ab Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
US7371364B2 (en) 2003-08-15 2008-05-13 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
JP2007512321A (ja) * 2003-11-24 2007-05-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
JP2007526300A (ja) * 2004-03-04 2007-09-13 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
JP5280683B2 (ja) * 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物
CN102532264A (zh) * 2004-06-16 2012-07-04 通用电气医疗集团股份有限公司 基于肽的化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102504603A (zh) * 2011-10-20 2012-06-20 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途

Also Published As

Publication number Publication date
ES2358745T3 (es) 2011-05-13
ATE494913T1 (de) 2011-01-15
KR20070091609A (ko) 2007-09-11
MX2007006050A (es) 2007-11-14
DE602005025911D1 (de) 2011-02-24
JP2008520658A (ja) 2008-06-19
US20090208412A1 (en) 2009-08-20
RU2007118385A (ru) 2008-12-27
EP2243496A3 (en) 2012-12-26
WO2006054904A2 (en) 2006-05-26
NO20073039L (no) 2007-08-16
CN101107016B (zh) 2011-11-16
ZA200705043B (en) 2008-09-25
EP1814598B1 (en) 2011-01-12
BRPI0518328A2 (pt) 2008-11-11
CN101107016A (zh) 2008-01-16
WO2006054904A3 (en) 2007-04-05
AU2005307195A1 (en) 2006-05-26
JP2012207027A (ja) 2012-10-25
EP1814598A2 (en) 2007-08-08
JP5116480B2 (ja) 2013-01-09
US8182790B2 (en) 2012-05-22
IL182898A0 (en) 2007-08-19
EP2243496A2 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
JP2012207027A (ja) 造影剤
US9119885B2 (en) RGD-containing peptidomimetics and uses thereof
US8568689B1 (en) uPAR-targeting contrast agents
JP2010513476A (ja) 造影剤
JP5280682B2 (ja) ペプチド系化合物
WO2005044313A2 (en) Conjugates of angiotensin ii and an imaging moiety
JP2011505820A (ja) 線維症の非侵襲性の特異的イメージングのための、ポリペプチド、環状ポリペプチドおよびそれを含む医薬

Legal Events

Date Code Title Description
FZDE Discontinued